Abstract: Kallikrein-related peptidase (KLK) 14 is a serine protease linked to several pathologies including prostate cancer. We show that KLK14 has biphasic effects in vitro on activating and inhibiting components of the prostate cancer associated hepatocyte growth factor (HGF)/ Met system. At 5-10 nm, KLK14 converts pro-HGF to the two-chain heterodimer required for Met activation, while higher concentrations degrade the HGF α-chain. HGF activator-inhibitor (HAI)-1A and HAI-1B, which inhibit pro-HGF activators, are degraded by KLK14 when protease:inhibitor stoichiometry is 1:1 or the protease is in excess. When inhibitors are in excess, KLK14 generates HAI-1A and HAI-1B fragments known to inhibit pro-HGF activating serine proteases. These in vitro data suggest that increased KLK14 activity could contribute at multiple levels to HGF/Met-mediated processes in prostate and other cancers.
Kallikrein-related peptidase (KLK) 14 (Hooper et al., 2001; Yousef et al., 2001 ) is one of the 15 members of the human KLK family of trypsin-fold serine proteases which also includes the prostate cancer biomarker KLK3 (or prostate-specific antigen; PSA) (Dong et al., 2014) . KLK14 spans 267 residues incorporating a signal peptide, that instructs for secretion, and a short pro-sequence that is cleaved at Lys40-Ile41 to generate the catalytically active protease. Mature KLK14 has trypsin-like activity with preference for cleavage after Arg (Brattsand et al., 2005; Felber et al., 2005; Oikonomopoulou et al., 2006; Stefansson et al., 2006; Borgono et al., 2007b; Rajapakse and Takahashi, 2007; de Veer et al., 2012) and there is also evidence for low-level chymotrypsinlike activity (Brattsand et al., 2005; Felber et al., 2005) . KLK14 is a positive regulator of the proteolytic cascade that mediates skin desquamation, and the absence of its inhibition is implicated in the skin barrier disorder Netherton syndrome (Prassas et al., 2015) . In addition, serum KLK14 levels are significantly elevated in prostate cancer patients compared with healthy men, and tissue levels correlate with prostate tumor status and are associated with disease progression defined by PSA relapse (Borgono et al., 2007b; Rabien et al., 2008) . A functional link between increased KLK14 expression and prostate cancer is suggested by its regulation of proteins that modulate progression of this malignancy. For example, KLK14 cleaves insulin-like growth factor binding proteins, thereby increasing the availability of insulin-like growth factor (IGF) to promote cell proliferation (Borgono et al., 2007b) . In addition, KLK14 modifies the prostate cancer microenvironment via degradation of the androgen transporter sex hormone-binding globulin (Sanchez et al., 2012) , disruption of cell-cell contacts via cleavage of desmoglein (Borgono et al., 2007a) , and degradation of extracellular matrix proteins including collagens, laminin, fibronectin and vitronectin (Borgono et al., 2007b; Rajapakse and Takahashi, 2007) .
Hepatocyte growth factor (HGF) mediates cell growth, cell motility and morphogenesis in numerous cell and tissue types via binding to the Met tyrosine kinase receptor (Cecchi et al., 2012) . In prostate cancer HGF is abundantly expressed by stromal cells present within the tumor microenvironment and serum levels are a strong predictor of metastasis to lymph nodes and disease recurrence (Gupta et al., 2008; Yasuda et al., 2009; Varkaris et al., 2011) . Met is overexpressed by malignant cells in primary tumors and is associated with high Gleason grade and tumor vascularization, and potentially tumor stage (Nakashiro et al., 2003; Strohmeyer et al., 2004; Jacobsen et al., 2013) . Thus, paracrine signaling via the actions of stroma-produced HGF on the Met receptor, which is elevated on the surface of malignant cells, is thought to be important in prostate cancer progression and metastasis (Trusolino et al., 2010) . HGF is produced as a pro-factor requiring activation to generate a two-chain heterodimer that includes an α-chain, containing four kringle domains, and a β-chain that has homology to trypsin-fold serine proteases. Activation occurs at Arg494-Val495 and is mediated by the circulating Arg/Lys-specific trypsin-fold serine protease HGF-activator (HGFA) (Miyazawa, 2010) and the plasma membrane serine proteases matriptase (Lee et al., 2000; Kirchhofer et al., 2003) and hepsin (Herter et al., 2005; Kirchhofer et al., 2005) . The actions of these serine proteases in initiation of the HGF/Met signaling axis are commonly negatively regulated by the Kunitztype inhibitors HGFA-inhibitor (HAI)-1, which has two variants HAI-1A and HAI-1B, and HAI-2 (Kawaguchi and Kataoka, 2014) . These inhibitors block proteolysis via tight association, as a pseudo-substrate, with the active site of the serine protease (Shia et al., 2005) . The roles of HAI-1 and HAI-2 in prostate cancer are not yet well defined and recent expression studies suggest potentially disparate roles for these inhibitors. For example, in contrast with the usual paradigm that reduced protease inhibitor levels contribute to protease-mediated processes in cancer progression, HAI-1 protein levels are higher in serum of patients with prostate cancer compared with men who have benign prostatic hyperplasia, and are also elevated in men who have metastasis and castrate resistant prostate cancer compared to patients with organ-confined disease (Nagakawa et al., 2006) . Similar changes were reported in prostate tumors with HAI-1 protein levels higher in patients with prostate cancer compared with BPH (Warren et al., 2009; Yasuda et al., 2013) . In contrast with HAI-1 expression, levels of HAI-2 protein are significantly decreased in malignant lesions compared with normal and benign lesions, with the most poorly differentiated tumors exhibiting the lowest levels of expression (Bergum and List, 2010; Tsai et al., 2014) .
The overlapping elevated expression of KLK14 and HGF in prostate cancer, and the specificity that KLK14 has for cleavage after Arg residues, which potentially includes the canonical activation site of pro-HGF (Arg494-Val495), prompted us to explore the role of KLK14 in the regulation of the HGF/Met system. For this purpose we generated and purified recombinant KLK14 from insect cells, first characterizing its enzymatic properties, then evaluating its impact in vitro on pro-HGF and the inhibitors HAI-1A and HAI-1B. To generate a suitable KLK14 expression construct, the previously cloned coding sequence (Hooper et al., 2001) , including the signal and pro-region sequence, was cloned in-frame in a pIB/V5-His expression vector (Invitrogen, Life Technologies Australia Pty Ltd, Mulgrave, Victoria, Australia) generating KLK14 with a carboxyl-terminal V5 tag (GKPIPNPLLGLDST) and six histidine residues. Insect Spodoptera frugiperda Sf9 cells (Gibco, Life Technologies, Mulgrave, Victoria, Australia) were stably transfected with the KLK14-V5-His construct and KLK14 was purified from the conditioned media using Ni-NTA Superflow resin (Qiagen, Doncaster, Victoria, Australia) eluting in the manufacturer's supplied elution buffer ( Figure 1A ). Pooled fractions of purified recombinant KLK14 were concentrated and dialyzed at 4°C against 5 mm NaH 2 PO 4 , 95 mm Na 2 HPO 4 , 0.01% (v/v) Tween20, pH 8.0 (Borgono et al., 2007b) . Activation was then performed by incubating KLK14 with the metalloprotease thermolysin (Calbiochem, San Diego, CA, USA) in the ratio 1:12.5 (thermolysin:KLK4) for 90 min at 37°C. Activation was apparent from the reduction in molecular weight of KLK14 of ~4 kDa as a result of loss of the pro-domain ( Figure 1B ). For comparison we employed thermolysinactivated recombinant KLK4, generated and purified as previously described (Ramsay et al., 2008) , and bovine trypsin ( Worthington Biochemical, Lakewood, NJ, USA), or the soluble auto-activating form of hepsin lacking its intracellular and transmembrane domains (generously provided by Dr. Daniel Kirchhofer, Genentech Inc., San Francisco, CA, USA). The proportion of active KLK4, KLK14, trypsin and hepsin present in relevant assays was determined by incubating protease (300 nm) with the suicide pseudo-substrate 4-methylumbelliferyl 4-guanidinobenzoate (MUGB; 1 μm) (Jameson et al., 1973) in 50 mm Tris, 50 mm NaCl, pH 8.8, 0.01% (v/v) Tween20 for 10 min at 37°C. Stoichiometric 1:1 release of fluorescent 4-MU from MUGB for every active protease molecule was measured using a POLARstar plate reader (BMG Labtech, Mornington, Victoria, Australia) by excitation at 355 nm with emission at 460 nm. Concentration of active protease was calculated using the relative fluorescence against a standard curve generated from known concentrations of 4-MU (0-1 μm).
Kinetic parameters were assessed using the synthetic tri-peptide substrate N-tert-butoxycarbonyl-Gln-Ala-Arg/7-amino-4-methylcoumarin (QAR-AMC), which is known to be efficiently hydrolyzed by KLK14 (Borgono et al., 2007b; Rajapakse and Takahashi, 2007) . The assay relies on hydrolysis of the bond between the P1 Arg residue releasing fluorescent AMC. Active KLK14 (12 nm), KLK4 (12 nm) and trypsin (0.4 nm) were incubated at 37°C with increasing concentrations (0.001-1 mm) of QAR-AMC, with fluorescence measured each minute for 20 min using a plate reader with 380 nm excitation and emission at 460 nm. A standard curve of fluorescence generated from known concentrations of AMC was used to determine the rate of hydrolysis. Employing non-linear regression and GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA), the Michaelis-Menten enzyme kinetics model was used to calculate the substrate concentration ([S]) at which reaction velocity is half maximal, K M , and the maximal reaction velocity, V max , and to derive, using the protease concentration and V max , the substrate per mole cule of protease turnover rate, k cat , and the ratio k cat /K M , as a measure of catalytic efficiency. As shown in Figure 1C , KLK14 has a high K M of 258 μm, suggesting a lower affinity for the substrate than either KLK4 or trypsin. The substrate turnover rate of k cat for KLK14 is higher than that of KLK4, which yields a higher catalytic efficiency, k cat /K M , of 4.7 × 10 4 m
, for KLK14 under the conditions tested. As expected, trypsin had the lowest K M and highest k cat and, as a result, the highest catalytic efficiency for the substrate QAR-AMC.
Interestingly, using the same substrate and assay parameters, Borgono and colleagues obtained a k cat /K M ~3-fold higher, at 14. , for recombinant KLK14 generated from yeast (Borgono et al., 2007b) , than the value obtained by us. This difference may be due to differences in the approaches used to measure active levels of KLK14. Whereas we employed the suicide pseudo-substrate MUGB, Borgono and colleagues used α1-antitrypsin and subsequent reduction in QAR-AMC hydrolysis to monitor levels of active KLK14. It is also possible that differences in k cat /K M values may be due to differences in N-glycosylation. Borgono and co-workers showed that recombinant KLK14 from P. pastoris is not post-translationally modified (Borgono et al., 2007b) , even though the protein sequence contains a consensus N-glycosylation site at Asn184-Ile-Ser. As N-glycosylation is known to alter enzyme activity (Skropeta, 2009 ), we further examined this issue by assessing the N-linked glycan content of KLK14 from insect cells by treating the purified protease with the enzyme peptide-N-glycosidase F (PNGase F), which removes these modifications from glycoproteins. As controls, we examined the effect of PNGase F on insect cell generated recombinant KLK4, as well as KLK14 and KLK4 that were transiently expressed by monkey kidney Cos-7 cells. As shown in Figure 1D , both insect cellexpressed proteases contained ~2 kDa of N-glycosylation, whereas this modification was not apparent from KLK14 and KLK4 transiently expressed by mammalian cells. It is not yet known whether this N-glycan content could alter protease:substrate interactions sufficiently to reduce the kinetics of insect cell expressed KLK14 compared with the non-glycosylated protease from yeast. However, N-glycosylation is required for matriptase autoactivation (Oberst et al., 2003; Miyake et al., 2010) , and attachment of aberrant N-glycan structures increases matriptase stability and metastasis (Ihara et al., 2002 (Ihara et al., , 2004 Ito et al., 2006) . To examine the role of KLK14 in activation of pro-HGF, increasing concentrations of the activated protease were incubated with the recombinant growth factor. Hepsin and KLK4 were assayed concurrently as examples of serine proteases that, respectively, activate (Herter et al., 2005; Kirchhofer et al., 2005; Owen et al., 2010) and degrade (Mukai et al., 2008) pro-HGF. Active protease from 0.1 to 100 nm was incubated with recombinant pro-HGF (1 μm) for 4 h at 37°C. Reaction mixtures were resolved by SDS-PAGE under reducing conditions then transferred onto nitrocellulose membranes and stained using Coomassie Blue R-250 (Sigma-Aldrich Pty Ltd, Castle Hill, NSW, Australia) to visualize protein bands. As shown in Figure 2A , KLK14 cleavage generates pro-HGF fragments in a concentration-dependent manner. Between KLK14 concentrations of 1 and 5 nm (protease:substrate ratio 1:1000 and 1:200), pro-HGF is converted to the two-chain heterodimer, with the protein fragments the same as reported when HGFA, matriptase and hepsin generate active HGF (Lee et al., 2000; Kirchhofer et al., 2005; Miyazawa, 2010) . We are yet to confirm that KLK14 mediated cleavage of pro-HGF occurs at the canonical activation site Arg494-Val495. At higher concentrations (10-100 nm; protease:substrate ratio 1:100 to 1:10), the HGF α-chain is completely degraded and the β-chain remains largely intact. As expected, hepsin demonstrates efficient concentration-dependent conversion of pro-HGF to the two-chain form ( Figure 2B ). At concentrations of hepsin as low as 0.1 nm (molar ratio of 10 000:1), there is near complete conversion of pro-HGF. In contrast with the effect of KLK14, even at higher hepsin concentrations there was little evidence of degradation of the HGF α-chain ( Figure 2B ). At concentrations up to 10 nm, KLK4 demonstrates little activity toward pro-HGF, and at higher concentrations it proceeds to degrade the HGF α-chain ( Figure 2C ). These data suggest the possibility that KLK14 has a biphasic role in regulation of pro-HGF that involves activation when the substrate is in vast excess (protease:substrate ratio 1:1000 to 1:200) and degradation as pro-HGF concentration increases (protease:substrate ratio 1:100 to 1:10).
We next explored KLK14 regulation of mechanisms that negatively impact on HGF/Met signaling. This involved examination of HAI-1A and HAI-1B as inhibitors and as substrates of KLK14. We selected HAI-1 for analysis, and not HAI-2, because levels of the former are elevated in prostate cancer, whereas HAI-2 levels are decreased (Nagakawa et al., 2006; Warren et al., 2009; Bergum and List, 2010; Yasuda et al., 2013; Tsai et al., 2014) . Inhibition was examined by assessing the impact of increasing concentrations of the inhibitors on KLK14 cleavage of the tri-peptide substrate QAR-AMC. The assay employed soluble forms of HAI-1A and HAI-1B that lack transmembrane and intracellular regions (Kirchhofer et al., 2003; Fan et al., 2005) (provided by Dr. Daniel Kirchhofer). Each inhibitor was incubated over the concentration range 0.25-50 nm with active KLK14 (5 nm) for 30 min at 37°C before addition of QAR-AMC (200 μm). Fluorescence of released AMC was measured as detailed above. As shown in Figure 3A , there is no inhibition of KLK14 up to equimolar concentrations (5 nm) of HAI-1A or HAI-1B. As the reaction shifts to containing excess inhibitor, KLK14 is mildly inhibited, with inhibition of ~35% and ~26% obtained when HAI-1A and HAI-1B, respectively, were present at 10-fold excess over protease. To monitor KLK14 interactions with HAI-1A and HAI-1B, the protease and inhibitor were incubated in molar ratios of 1:0.5, 1:1, 1:5 and 1:10 for 30 min at 37°C. Reaction mixtures were resolved by SDS-PAGE under reducing conditions then transferred onto nitrocellulose membranes and stained using Coomassie Blue R-250. In contrast with the proteases HGFA (Kataoka et al., 2002) , prostasin and matriptase (Kiyomiya et al., 2006) that form stable complexes with HAI-1, there was no evidence of complex formation between KLK14 and HAI-1A or HAI-1B ( Figure 3B and C) . Instead, each inhibitor is extensively degraded when the stoichiometry is 1:1 or the protease is in excess. When HAI-1A and HAI-1B are in excess, KLK14 processing generates predominant products at ~15 and 40 kDa with less intense protein bands at ~22 and 35 kDa. It has previously been reported that the 40 kDa fragment contains Kunitz domain 1 of HAI-1 (Lin et al., 1999) which is the region that mediates inhibition of the membrane anchored serine protease and pro-HGF activator TMPRSS13 (Hashimoto et al., 2010) and forms a stable complex with another activator matriptase (Benaud et al., 2001) . Thus, when the inhibitor is in excess, KLK14 releases HAI-1A and HAI-1B fragments that likely mediate inhibition of pro-HGF convertases.
In summary, we generated, purified and activated KLK14 from an insect cell expression system, and used this to examine the role of the protease in the regulation of components of the HGF/Met receptor system. The lower catalytic efficiency observed by us against a peptide substrate for insect cell expressed KLK14, compared with the previously reported yeast expressed protease (Borgono et al., 2007b) , is possibly due to N-glycosylation present on the former but not the latter. If this is the case it is possible that the nonglycosylated KLK14 observed by us from mammalian cells, could have even greater activity against the macro-molecular substrates pro-HGF and HAI-1A and HAI-1B than we observed above. Our data indicate that KLK14 has biphasic effects on pro-HGF, and HAI-1A and HAI-1B in vitro. When pro-HGF is in vast excess it is activated by KLK14, and as the substrate concentration increases above a threshold level (protease:substrate ratio above 1:200), HGF is inactivated. Similarly, HAI-1A and HAI-1B are extensively degraded when the protease:inhibitor stoichiometry is 1:1, or KLK14 is in excess. When the inhibitors are in excess, KLK14 processing generates fragments that likely mediate inhibition of pro-HGF convertases. These data suggest that increased KLK14 activity could contribute at multiple levels to HGF/ Met-mediated processes in prostate and other cancers. Further experiments are required to examine this in disease relevant models. 
